Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates-Reference-Cited by-同舟云学术

Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates

Published:2015-05-05 Issue:4 Volume:17 Page:1025-1032
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Polak Sebastian,Pugsley Michael K.,Stockbridge Norman,Garnett Christine,Wiśniowska Barbara

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

http://link.springer.com/content/pdf/10.1208/s12248-015-9773-1.pdf

Reference76 articles.

1. Stockbridge N, Morganroth J, Shah RR, Garnett C. Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated? Drug Saf. 2013;36(3):167–82.

2. Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J. 2014;167(3):292–300.

3. Shah RR. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundam Clin Pharmacol. 2002;16(2):147–56.

4. Letsas KP, Tsikrikas S, Letsas GP, Sideris A. Drug-induced proarrhythmia: QT interval prolongation and Torsades de Pointes. Hosp Chronicles. 2011;6(3):118–22.

5. Gintant G. An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther. 2011;129(2):109–19.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Off target toxicities and links with physicochemical properties of medicinal products, including antibiotics, oligonucleotides, lipid nanoparticles (with cationic and/or anionic charges). Data review suggests an emerging pattern;Toxicology Letters;2023-08

2. Multitargeting in cardioprotection: An example of biaromatic compounds;Archiv der Pharmazie;2023-06-22

3. Inhibition of the hERG potassium ion channel by different non-nucleoside human cytomegalovirus polymerase antiviral inhibitor series and the exploration of variations on a pyrroloquinoline core to reduce cardiotoxicity potential;Bioorganic & Medicinal Chemistry;2023-05

4. Сardioprotective agents with biaromatic structure. Part 4. Potassium hERG channels blockers and modulators;Pharmacokinetics and Pharmacodynamics;2023-01-18

5. Сardioprotective agents with biaromatic structure. Part 1. Calcium channel blockers;Pharmacokinetics and Pharmacodynamics;2022-02-21